Non-coding RNAs in vascular disease - from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Jan Fiedler, Andrew H. Baker, Stefanie Dimmeler, Stephane Heymans, Manuel Mayr, Thomas Thum*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Web of Science)

Abstract

Non-coding RNAs are increasingly recognized not only as regulators of various biological functions but also as targets for a new generation of RNA therapeutics and biomarkers. We hereby review recent insights relating to non-coding RNAs including microRNAs (e.g. miR-126, miR-146a), long non-coding RNAs (e.g. MIR503HG, GATA6-AS, SMILR), and circular RNAs (e.g. cZNF292) and their role in vascular diseases. This includes identification and therapeutic use of hypoxia-regulated non-coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth muscle cell signalling, age-related non-coding RNAs, and non-coding RNAs involved in the regulation of mitochondrial biology and metabolic control. Finally, we discuss non-coding RNA species with biomarker potential.
Original languageEnglish
Pages (from-to)1281-1286
Number of pages6
JournalCardiovascular Research
Volume114
Issue number10
DOIs
Publication statusPublished - 1 Aug 2018

Keywords

  • Non-coding RNA
  • Vascular disease
  • Biomarker
  • CIRCULATING MICRORNAS
  • CARDIAC-HYPERTROPHY
  • CELL-PROLIFERATION
  • DYSFUNCTION
  • INFARCTION
  • ATHEROSCLEROSIS
  • OVEREXPRESSION
  • IDENTIFICATION
  • INHIBITION
  • ACTIVATION

Cite this